Nanomedicine and Pharmaceutical Nanotechnology

Biography

Dr. Jorge Gonzalez Borroto (PharmD, Ph.D) is Senior Nonclinical Toxicologist and Pharmacovigilance Officer in the pharmaceutical company Ferrer Internacional S.A., Barcelona, Spain. He accomplished his Ph.D in Genetic, specialization in Genetic Toxicology from Autonomous University of Barcelona (UAB, Barcelona, Spain). Scientifically, He has been interested in nonclinical toxicology and safety assessment using in vitro and in vivo tests in several projects supporting the clinical development phases of new drugs or new drugs-formulations combining new methodologies, new testing strategies, relevant animal’s models and use of biomarkers for safety assessment. He has been, implicated in post-marketing safety assessment and strategies for risk management of marketed medicines through pharmacovigilance procedures inside a pharmaceutical company. Technically, He has been involved in development of new testing strategies for predictive toxicology through validation of novel tests and cell-based assays in drug discovery, development of new biomarkers for assessment of toxicological effects in animal models and integration of in vitro and in vivo safety results during drugs development to obtain safer drugs for human use. He has outstanding scientific accomplishments with multiple research projects, publications in prestigious toxicology journals and various presentations in both national and international conferences. Furthermore He is acting as Expert in several European organizations (such as, European Commission: Sixth and Seventh Framework Programme, European Food Safety Authority, Innovative Medicines Initiative) supporting different scientific activities.

Research Interest

Toxicology Evaluation in Drug Development; New Methodologies for Predictive Toxicology; New Animals Models for Safety Evaluation; Biomarkers for Drug Safety Assessment.